Compounds > 1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol
Page last updated: 2024-09-03

1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol and Prostatic Neoplasms

1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol has been researched along with Prostatic Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Henry, JM; Isaacs, JT1

Other Studies

1 other study(ies) available for 1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol and Prostatic Neoplasms

ArticleYear
Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
    The Journal of urology, 1989, Volume: 142, Issue:1

    Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Male; Misonidazole; Photochemotherapy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Rats; Tumor Stem Cell Assay

1989